Our analysis revealed that the primary pathways associated with the central targets of CEP in the treatment of BPH are closely related to the PI3K-AKT signaling pathway, EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, HIF-1 signaling pathway, and mTOR signaling pathway. This evidence concerns the gene AKT1 and benign prostatic hyperplasia.